Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells

Diabetes Research and Clinical Practice

Volumn 77, Issue 3 SUPPL., 2007, Pages

  Yamamoto, Yasuhiko ^a   Yonekura, Hideto ^a,b   Watanabe, Takuo ^a   Sakurai, Shigeru ^a   Li, Hui ^a   Harashima, Ai ^a   Myint, Khin Mar ^a   Osawa, Mari ^a   Takeuchi, Akihiko ^a   Takeuchi, Masayoshi ^c   Yamamoto, Hiroshi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c HOKURIKU UNIVERSITY   (Japan)

Author keywords

Advanced glycation endproducts (AGE); Diabetes; Receptor; Vascular complications; Vascular endothelial growth factor (VEGF)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDEHYDE; GLYCERALDEHYDE; MESSENGER RNA; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; AUTOOXIDATION; CELL PROLIFERATION; CELL STRAIN COS7; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DNA SYNTHESIS; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCATION; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

ALDEHYDES; ANIMALS; CELL LINE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; DNA REPLICATION; ENDOTHELIUM, VASCULAR; HAPLORHINI; HUMANS; LIGANDS; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURFACE PLASMON RESONANCE; UMBILICAL VEINS;

EID: 34547700355     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.01.030     Document Type: Article

References (36)

1. Brownlee M., Cerami A., and Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318 (1988) 1315-1321
2. Al-Abed Y., Kapurniotu A., and Bucala R. Advanced glycation end products: detection and reversal. Methods Enzymol. 309 (1999) 152-172
3. Wells-Knecht K.J., Zyzak D.V., Litchfield J.E., Thorpe S.R., and Baynes J.W. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34 (1995) 3702-3709
4. Thornalley P.J. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol. 27 (1996) 565-573
5. Glomb M.A., and Monnier V. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J. Biol. Chem. 270 (1995) 10017-10026
6. Takeuchi M., and Makita Z. Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo. Curr. Mol. Med. 1 (2001) 305-315
7. Takeuchi M., Makita Z., Bucala R., Suzuki T., Koike T., and Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol. Med. 6 (2000) 114-125
8. Takeuchi M., Yanase Y., Matsuura N., Yamagishi S., Kameda Y., Bucala R., et al. Immunological detection of a novel advanced glycation end-product. Mol. Med. 7 (2001) 783-791
9. Takeuchi M., Bucala R., Suzuki T., Ohkubo T., Yamazaki M., Koike T., et al. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 59 (2000) 1094-1105
10. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267 (1992) 14987-14997
11. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267 (1992) 14998-15004
12. Yamagishi S., Yonekura H., Yamamoto Y., Katsuno K., Sato F., Mita I., et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272 (1997) 8723-8730
13. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., and Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 41 (1998) 1435-1441
14. Yamagishi S., Hsu C.C., Taniguchi M., Harada S., Yamamoto Y., Ohsawa K., et al. Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy. Biochem. Biophys. Res. Commun. 213 (1995) 681-687
15. Tsuji H., Iehara N., Masegi T., Imura M., Ohkawa J., Arai H., et al. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem. Biophys. Res. Commun. 245 (1998) 583-588
16. Yamamoto Y., Kato I., Doi T., Yonekura H., Ohashi S., Takeuchi M., et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 108 (2001) 261-268
17. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
18. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin Md.J., Li H., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370 (2003) 1097-1109
19. Myint K.M., Yamamoto Y., Doi T., Kato I., Harashima A., Yonekura H., et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low molecular weight heparin. Diabetes 55 (2006) 2510-2522
20. Harashima A., Yamamoto Y., Cheng C., Tsuneyama K., Myint K.M., Takeuchi A., et al. Identification of mouse ortholog of endogenous secretory receptor for advanced glycation endproducts: structure, function and expression. Biochem. J. 396 (2006) 109-115
21. Tanaka N., Yonekura H., Yamagishi S., Fujimori H., Yamamoto Y., and Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 275 (2000) 25781-25790
22. Fraker P.J., and Speck Jr. J.C. Protein and cell membrane iodinations with a sparingly soluble chloroamide 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem. Biophys. Res. Commun. 80 (1978) 849-857
23. Nagai R., Matsumoto K., Ling X., Suzuki H., Araki T., and Horiuchi S. Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes 49 (2000) 1714-1723
24. Nomura M., Yamagishi S., Harada S., Hayashi Y., Yamashima T., Yamashita J., et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J. Biol. Chem. 270 (1995) 28316-28324
25. Yonekura H., Sakurai S., Liu X., Migita H., Wang H., Yamagishi S., et al. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J. Biol. Chem. 274 (1999) 35172-35178
26. ε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274 (1999) 31740-31749
27. Thornalley P.J., Langborg A., and Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344 (1999) 109-116
28. Nagai R., Hayashi C.M., Xia L., Takeya M., and Horiuchi S. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J. Biol. Chem. 277 (2002) 48905-48912
29. Abeyama K., Eng W., Jester J.V., Vink A.A., Edelbaum D., Cockerell C.J., et al. A role for NF-kappaB-dependent gene transactivation in sunburn. J. Clin. Invest. 105 (2000) 1751-1759
30. Yoshida S., Ono M., Shono T., Izumi H., Ishibashi T., Suzuki H., et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell. Biol. 17 (1997) 4015-4023
31. Treins C., Giorgetti-Peraldi S., Murdaca J., Van E., and Obberghen. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J. Biol. Chem. 276 (2001) 43836-43841
32. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108 (2001) 949-955
33. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270 (1995) 25752-25761
34. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
35. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 (1996) 685-691
36. Sousa M.M., Yan S.D., Stern D., and Saraiva M.J. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor κB (NF-κB) activation. Lab. Invest. 80 (2000) 1101-1110